Esperanza Arriola Arellano, Verónica Díaz Díaz, Joaquín José Cabrera Rodríguez

Arellano et al. J Clin Transl Res 2020; 6(S4):6

Published online: October 29, 2020


Background. Patients with unresectable stage III non-small cell lung cancer constitute a heterogeneous group in which the available treatments may range from radical therapies with radio-chemotherapy to supportive treatments depending on the extent of the disease and comorbidities present. For years the standard treatment based on the combination of chemotherapy and radiotherapy has remained unchanged and survival outcomes have been poor.
Aim. Recent advances in molecular biology and radiotherapy technology have resulted in improved survival. This article reviews the treatments that constitute current standard treatment in unresectable advanced lung cancer, and the situations and indications for the management of patients who are not candidates for radical therapy.
Relevance for patients. Although unresectable lung cancer does not have a good prognosis, new drugs and new technologies in radiation oncology can offer treatment options adapted to the patient's clinical situation, ranging from therapies administered with radical intent to others aimed mainly at improving the patient's quality of life, which, judiciously chosen, will provide optimal management of the patient.


Author Affiliation

1. Department Medical Oncology. Universitary Hospital Puerta del Mar. Cádiz. Spain
2. Department of Radiation Oncology. Universitary Hospital Puerta del Mar. Cádiz. Spain.
3. Department of Radiation Oncology. Universitary Hospital of Badajoz. Badajoz. Spain. 

*Corresponding author
Joaquín José Cabrera Rodríguez
Department of Radiation Oncology. Universitary Hospital of Badajoz. 06080. Badajoz. Spain
Tel: +34 924 218100 (48542)
Fax: +34 924 219871

Handeling editor:
Michal Heger
Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China


Epub ahead of print (715.3 KB)